Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamo

Pathologic complete responses seen in 63% of patients in phase II data

Related Keywords

Germany , Australia , University Medical Center , Texas , United States , Houston , Netherlands , Massachusetts , Amsterdam , Noord Holland , Mike Bassett , Neil Gross , Leiden University Medical Center , Md Anderson Cancer Center , Netherlands Cancer Institute , European Society For Medical Oncology , Cancer Center , European Society , Medical Oncology , New England Journal , Christian Blank , England Journal , Englj Med ,